| Names | |
|---|---|
| IUPAC name Methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-[(E)-3,4-dimethylpent-2-enoyl]oxy-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate | |
| Other names Bruceantine | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID | |
| UNII | |
| |
| |
| Properties | |
| C28H36O11 | |
| Molar mass | 548.585 g·mol−1 |
| Melting point | 225–226 °C (437–439 °F; 498–499 K) [1] |
| Hazards | |
| Lethal dose or concentration (LD, LC): | |
LD50 (median dose) | mouse (male, IV) 1.95 mg/kg mouse (female, IV) 2.58 mg/kg [1] |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Bruceantin is a chemical compound that was first isolated from the plant Brucea antidysenterica in 1973. [2] Chemically, it is classified as a secotriterpenoid and a quassinoid.
Bucreantin has attracted interest as a potential antitumor drug because of its antineoplastic activity. [3] It inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis. [3] Bruceantin also has antibiotic, antiamoebic, [4] and antimalarial activity. [3]
Phase I and II clinical trials were conducted for the treatment of metastatic breast cancer and melanoma, but tumor regression was not observed and clinical development was terminated. [5] [6]